Gouty arthritis – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:20:32 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Gouty arthritis – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 A study comparing dotinurad and allopurinol for lowering uric acid levels in adults with gout and high uric acid in the blood. https://clinicaltrials.eu/trial/a-study-comparing-dotinurad-and-allopurinol-for-lowering-uric-acid-levels-in-adults-with-gout-and-high-uric-acid-in-the-blood/ Thu, 30 Apr 2026 13:08:15 +0000 https://clinicaltrials.eu/trial/a-study-comparing-dotinurad-and-allopurinol-for-lowering-uric-acid-levels-in-adults-with-gout-and-high-uric-acid-in-the-blood/ This study involves people with hyperuricemia associated with gout. Hyperuricemia means having too much uric acid in the blood, which can lead to gout, a condition that causes painful swelling in the joints. Gout occurs when uric acid crystals build up in the joints, leading to sudden attacks of pain, redness, and swelling. The study will compare two medications that lower uric acid levels in the blood. One medication is dotinurad, also known by its code name FYU-981, which is being tested to see how well it works. The other medication is allopurinol, which is already used to treat high uric acid levels and gout. Some participants will receive placebo instead of one of the active medications.

The purpose of this study is to evaluate how well dotinurad works in lowering uric acid levels in the blood at week 24 when compared with allopurinol in adults with hyperuricemia associated with gout. The study will measure the percentage of participants whose uric acid level drops below a certain target level. It will also look at how often gout attacks occur during the study and whether participants can maintain low uric acid levels without experiencing gout attacks that need treatment.

Participants in this study will take their assigned medication by mouth in capsule form for up to 64 weeks. The study medications will be given in a way that neither the participants nor the doctors will know which treatment each person is receiving until the study is complete. During the study, participants will have regular visits where blood tests will be done to measure uric acid levels, and any gout attacks will be recorded. The study will track how well the medications work in lowering uric acid and preventing gout attacks over time.

]]> Study on Gout Treatment: Comparing Allopurinol, Benzbromarone, and Febuxostat in Patients with Gout in Remission https://clinicaltrials.eu/trial/study-on-gout-treatment-comparing-allopurinol-benzbromarone-and-febuxostat-in-patients-with-gout-in-remission/ Wed, 29 Apr 2026 14:27:32 +0000 https://clinicaltrials.eu/trial/study-on-gout-treatment-comparing-allopurinol-benzbromarone-and-febuxostat-in-patients-with-gout-in-remission/ This clinical trial is focused on studying gout, a condition characterized by painful joint inflammation due to the accumulation of uric acid crystals. The study will explore the effects of three different medications used to lower uric acid levels: allopurinol, benzbromarone, and febuxostat. These medications are taken orally and are commonly used to manage gout by reducing uric acid in the body.

The purpose of the study is to compare two strategies: continuing urate-lowering therapy versus stopping it in patients whose gout is in remission. Remission means that the patient has not experienced any gout flares, visible uric acid deposits called tophi, or significant pain due to gout for at least 12 months. The study will last for 24 months, during which participants will be monitored to see if they continue to meet the criteria for remission.

Participants will be randomly assigned to either continue their current urate-lowering medication or to stop taking it. The study will assess how many participants in each group remain in remission during the last six months of the study. This will help determine the best strategy for managing gout in remission. Additionally, the study will evaluate the cost-effectiveness of these strategies, which means it will look at the balance between the benefits of the treatment and its costs.

]]>